Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience

Real‑world evidence from Italy consistently confirms that tildrakizumab provides durable effectiveness and a favorable safety profile across a broad spectrum of patients, often matching or exceeding outcomes reported in pivotal trials. The availability of two approved dosing options may support personalized treatment approaches, although current evidence remains observational and further long-term studies are required to define the full clinical implications.